What is the ROE (Return on Equity) of Agenus this year?
The ROE of Agenus this year is 1.53 undefined.
Agenus ROE 2024
Agenus ROE
1.53
Ticker
AGEN
ISIN
US00847G7051
WKN
A1JLKZ
In 2024, Agenus's return on equity (ROE) was 1.53, a -57.32% increase from the 3.59 ROE in the previous year.
Agenus Aktienanalyse
What does Agenus do?
Agenus Inc is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company was founded in 1994 and is headquartered in Lexington, Massachusetts. Agenus started as a small start-up company focusing on the research of antibodies against chronic viral diseases. In 2000, the company developed the first approved therapeutic vaccine against cervical cancer in collaboration with GlaxoSmithKline. Since then, Agenus has expanded its business to the discovery, development, and commercialization of novel antibody and immunotherapies. The company has brought many groundbreaking medications to the market, including a cancer immunotherapy called Prophage, which is approved for the treatment of glioblastoma, an aggressive brain tumor. Agenus' business model focuses on the development of immunotherapies that utilize the body's immune system to fight against cancer or other diseases. The company's research and development programs are divided into three areas: antibody development, immunotherapy, and preclinical developments. Agenus has a comprehensive library of antibodies and utilizes them to develop new and innovative antibodies and antibody conjugates that can be used to treat cancer and autoimmune diseases. The company has also developed a range of immunotherapies aimed at supporting the body's immune system in fighting against cancer and other diseases, including therapies targeting checkpoint inhibitors that enhance the body's immune response to cancer cells. In addition, Agenus has a broad portfolio of preclinical programs aimed at developing new drugs and therapies for the treatment of cancer and other diseases. Agenus has introduced a range of products to the market that can be used for the treatment of cancer and other diseases, including Prophage, a personalized cancer vaccine tailored to each patient for the treatment of glioblastoma. Other products include Zalifrelimab, a checkpoint inhibitor that aims to enhance the body's immune response to cancer, INCAGN2385, another checkpoint inhibitor that enhances T-cell activity in the body, and INCAGN1949, an antibody therapy targeting the GITR protein that can help enhance the immune response against cancer cells. In summary, Agenus is a leading biotech company specialized in the development of immunotherapies for the treatment of cancer and other serious diseases. The company has a long history in antibody research and development and has expanded its efforts to develop immunotherapies. Agenus has a comprehensive library of antibodies and has introduced a range of products to the market for the treatment of cancer and other diseases. With a broad portfolio of products and preclinical programs, Agenus remains a key player in the field of immunotherapies and is expected to drive further groundbreaking developments in the future. Agenus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Agenus's Return on Equity (ROE)
Agenus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Agenus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Agenus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Agenus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Agenus stock
How has the Return on Equity (ROE) of Agenus developed compared to the previous year?
The ROE of Agenus has increased by -57.32% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Agenus?
A high ROE indicates that Agenus generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Agenus?
A low ROE can indicate that Agenus is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Agenus affect the company?
A change in ROE (Return on Equity) of Agenus can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Agenus?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Agenus?
Some factors that can influence Agenus's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Agenus pay?
Over the past 12 months, Agenus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Agenus is expected to pay a dividend of 0 USD.
What is the dividend yield of Agenus?
The current dividend yield of Agenus is .
When does Agenus pay dividends?
Agenus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Agenus?
Agenus paid dividends every year for the past 0 years.
What is the dividend of Agenus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Agenus located?
Agenus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Agenus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Agenus from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did Agenus pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of Agenus in the year 2023?
In the year 2023, Agenus distributed 0 USD as dividends.
In which currency does Agenus pay out the dividend?
The dividends of Agenus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Agenus
Our stock analysis for Agenus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Agenus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
